Top line decelerating.
+13.0% YoY versus +20.0% prior. 3y CAGR +15.4%.
+13.0%We use cookies
MainRatios uses cookies for essential site functions. With your consent, we also use analytics cookies including session replay sampling (PostHog, Google Analytics) and advertising cookies (Google AdSense). You can reject non-essential cookies, including the "sale" or sharing of personal information under CCPA, and you may withdraw consent at any time (GDPR). See our Privacy Policy for details.
All analysis on this page is for educational purposes only and does not constitute financial advice. Fair values are model-based estimates. Always do your own research.
2 of 3 legendary models say BUY DOCS — but Peter Lynch disagrees.
What would legendary investors pay for DOCS?
These figures are not quotes or opinions from Buffett, Graham, Lynch or the other investors. They are our own estimates, computed by applying the intrinsic-value formulas each investor is known for to this company’s financials.
For educational purposes only. Not a recommendation to buy or sell securities.
+13.0% YoY versus +20.0% prior. 3y CAGR +15.4%.
+13.0%Net margin 30.4% versus 39.1% prior (−8.7pp). Operating 33.3%.
30.4%P/E 20.8x — 55% below the 5y median of 46.4x. Forward 13.2x hints at EPS expansion next year.
20.8xBottom line: DOCS is rated BUY by 2 of 3 legendary models, with 0 holding and 1 flagging it overvalued, but earns a B sector grade (74/100) in Healthcare. Whether the premium is justified depends on which lens you trust. Drill into the valuation breakdown and sector ranking for the full picture.
The Question
Yes — Doximity, Inc.'s 20.6% ROE ranks above the S&P 500 median, and D/E 0.18 stays within healthy bounds.
Financial story
Yes — Doximity, Inc.'s 20.6% ROE shows strong capital efficiency, and its 0.18 debt-to-equity stays within healthy bounds.
2 of 3 legendary investor models rate DOCS a BUY. Fair value estimates and full investor breakdown are in the valuation tab.
Average fair value across qualifying models: $30. See the per-investor fair-value table in the valuation tab.
DOCS trades at 19.2x earnings. Sector context and per-investor signals are in the valuation tab.
DOCS and VKTX differ on P/E, ROE, and revenue growth. See the full DOCS vs VKTX compare matrix.
Buffett, Lynch, and Munger evaluate DOCS against their respective frameworks. Per-model fair value and reasoning are in the valuation tab.
DOCS's P/E ratio is 19.2x. 5-year P/E history is in the financials tab.
How does DOCS compare?
See exactly where DOCS ranks
Sign in to unlock the full sector ranking — free.
Sign in to see the rankingDOCS sits at #2 in Healthcare with a B grade (74/100).